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Drug delivery to treat ocular disorders locally is a challenging endeavor. Traditional ocular dosage form 
- eye drops - exhibits poor availability, consequently inefficient therapeutic response. The objective of 
the study was to formulate and characterize a ketorolac tromethamine ocular system with a prolonged 
release pattern based on liposomes as a vesicular carrier and to design once daily liquid preparation 
realizing the thermal in situ gelation principle. Liposomes were prepared by film hydration method. The 
influence of cholesterol concentration, pH and volume of hydration medium, and type and concentration 
of charging imparting agents were studied. Liposomes were characterized via, morphological examination, 
vesicular size, and encapsulation efficiency, and in vitro release performance, moreover its stability 
was assessed. The results obtained highlighted that liposomes showed a closed vesicular multi-lamellar 
structure. Ketorolac was successfully encapsulated within the liposomal structure in a cholesterol 
and charge inducing agent concentration-dependent behaviour. The dispersion of liposomes within 
thermosensitive Poloxamer in situ gel was able to retard the release of the drug by diffusion providing 
a controlled prolonged delivery. The liposomal formulations were physically stable for six months. 
Ketorolac tromethamine in situ liposomal gel representing an efficient alternative in terms of ocular 
retention and patient compliance when compared with conventional eye drops.
Uniterms: Ketorolac/characterization/formulation. Liposomes/stability study. Ocular delivery. 
Thermosensitive gel. Prolonged release.
INTRODUCTION
Ketorolac tromethamine, Figure 1, is one of the 
arylacetic acid derivatives group of non-steroidal anti-
inflammatory drugs which are potent cyclooxygenase 
inhibitors (Ahuja et al., 2008). It has been used in the 
management of several ocular disorders. Ketorolac 
is FDA approved treatment of ocular pain following 
corneal refractive surgery and surface ablation and other 
ocular conditions such as seasonal allergic conjunctivitis 
and postoperative inflammation (Robinson, Lee, 2011). 
Ketorolac, free acid, is sparingly soluble in water and, 
therefore, it is marketed in the form of tromethamine salt, 
which has a higher aqueous solubility (Thakur, Kashiv, 
2011). Ketorolac tromethamine is commercially available 
as eye drops. Instillation of 0.5% ketorolac tromethamine 
aqueous solution was associated with ocular irritation, 
evoked as burning and stinging (Sandoval et al., 2006). 
The main problem encounter eye drops as a local 
ocular drug delivery is its poor bioavailability due to short 
residence time on the eye surface as a result of several 
factors among them, preparation overflow from the eye 
surface specially upon blinking, dilution by tears, reflex 
lachrymation and systemic drug absorption through 
nasolacrimal drainage (Snell, 1998). In order to prevail 
over these limitations, numerous trials were carried out 
to prolong the contact time between the preparation and 
FIGURE 1 - Chemical structure of ketorolac tromethamine.
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the ocular surface such as ketorolac oily solution and 
ophthalmic ointment preparations had been studied and 
evaluated (Malhotra, Majumdar, 2006). Gelling systems 
were utilized for the same purpose as ion activated 
in situ gel (Vodithala et al., 2010), hydrogel system 
based on chitosan and carbopol 940 (Zaki et al., 2011), 
methylcellulose and hydroxypropyl methylcellulose in 
presence of sodium bicarbonate (Nanjawade, Manvi, 
Manjappa, 2007). Recently, Thakor et al. (2012), 
formulated ketorolac tromethamine in various in-situ 
gelling systems, which significantly improved ocular 
bioavailability as compared to conventional eye drops 
as proved through in vitro and in vivo studies through its 
longer precorneal residence time and ability to sustain 
drug release.
Phospholipid-based vesicles, i.e. liposomes, are 
biocompatible and biodegradable carrier system with 
almost no cytotoxicity. Moreover, it has the capability 
of enhancing drug solubility, stability and reduce drug 
adverse reactions (Schubert, 2002). From ophthalmic 
formulation point of view, liposomes are able to 
intimately contact the corneal and conjunctival surfaces 
and modify the tears dynamics which positively reflect 
on its ability to prolong the drug ocular availability and 
thus reducing the frequency of administration, the total 
drug applied and both the systemic and topical side 
effects which augment patient compliance to the drug 
regimen. On top of these merits, liposomal preparations 
are still a liquid formulation that are easily installed 
with no discomfort and can localize and maintain drug 
activity at the ocular surface for a longer period, thus 
allowing a controlled drug delivery (Van Der Bijl, Van 
Eyk, Meyer, 2001). Several research clusters investigated 
the utilization of liposomes as ocular system exemplified 
by the study of Mehanna, Elmaradny and Samaha (2009) 
who formulated ciprofloxacin loaded-liposomes using 
the reverse phase evaporation technique and studied 
five different factors affecting the entrapment efficiency; 
the results revealed that the most important factor was 
the molar concentration of cholesterol, Habi, Fouad, 
Fathalla (2008) prepared 2 mg/mL fluconazole loaded-
liposomes using reverse phases evaporation technique 
for the treatment of Candida keratitis in rabbits eyes and 
found that the liposomal formulation showed a better 
healing percentage over the same period of time. In 2014, 
Tahaa et al. (2014) studied several liposomal formulations 
containing ciprofloxacin and examined the influence of 
different types of phospholipids, cholesterol incorporation, 
incorporation of positively charge inducing agent, and 
ultrasonication on the liposomes properties and concluded 
that liposomal formulations showed more than three folds 
of improvement in drug ocular bioavailability compared 
with the commercial product.
The goal of the present study is to prepare, 
characterize and optimize an ocular liposomal formulation 
of ketorolac tromethamine as a potent anti-inflammatory 
drug for treatment of ocular conditions with a prolonged 
release. Furthermore, formulate the prepared liposomes 
in a thermo-sensitive gel. The physical stability of the 
optimized liposomal formulation along with the liposomal 
gel is evaluated upon storage at different temperatures.
MATERIAL AND METHODS
Material
Ketorolac tromethamine (assay<99.0%), Dicetyl 
phosphate, Stearylamine and Pluronic F 127(PF-127) were 
purchased from Sigma Aldrich (Steinheim, Switzerland). 
Lipoid E80, phosphatidylcholine from egg was received 
as a gift from Lipoid Company (Ludwigshafen, Germany). 
Cholesterol was purchased from Winlab (Leicestershire, 
UK). Spectrapore® 2 dialysis membrane form Spectrum 
laboratories Inc. (Houston, TX, USA). All other solvents 
and materials used were of analytical grade. 
Preparation of Ketorolac tromethamine-loaded 
liposomes
Liposomes were prepared using film hydration 
technique, which involves dissolving the organic soluble 
moieties (phospholipid, cholesterol and charge inducing 
agent) in an organic solvent, then evaporating this 
solvent by means of vacuum and gentle heat, leaving 
an even film on the walls of the round-bottom flask. 
The second major step is the ‘hydration’ that is carried 
out with an aqueous phase composed of water, drug and 
other water-soluble ingredients. This hydration causes 
immediate globulization of the phospholipid film where 
the lipid layer tends to form liposomes incorporating the 
aqueous phase either inside the bilayer of the liposomal 
wall and/or in the core of the lipid vesicle. The final step 
is the refrigeration of the formed liposomes to ensure 
intact vesicle formation.
Specifically, 100 mg phosphatidyl choline dissolved 
in chloroform, along with cholesterol, and other organic 
soluble ingredients. The flask is held in rotavapor under 
approximately -900 mbar, 50 °C, rotating at 45 rpm 
(Rotavapor, type V8000, Buchi, Switzerland) till the 
solvent is completely evaporated and an even film is 
formed. Hydration is achieved by addition of the aqueous 
phase including the ketorolac tromethamine (KT) 
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under normal pressure at 50 °C, rotating at 45 rpm, for 
20 minutes till the film is completely hydrated and the 
liposomes are formed, then stored in refrigerator for 24 
hours (Ghanbarzadeh, Valizadeh, Zakeri-Milani, 2013)a 3(2.
Separation of unentraped free ketorolac 
tromethamine 
Free ketorolac tromethamine separation from 
liposomal dispersion was performed using cooling 
ultracentrifuge (Sigma laboratory refrigerated centrifuge, 
3K-30, Germany) rotating at 17000 rpm, at a temperature 
of 1°C, for 90 minutes. The supernatant representing the 
unentraped ketorolac tromethamine was decanted then 
transferred to a volumetric flask suitably diluted and 
drug content was determined spectrophotometrically 
(Shimadzu UV 1601 PC spectrophotometer, Kyoto, 
Japan). Liposomes was redispersed with 1 mL distilled 
water and stored for further characterization (Mehanna, 
Elmaradny, Samaha,2010).
Optimization of ketorolac liposomal entrapment 
efficiency
In order to develop an optimized liposomal 
formulation with the highest entrapment efficiency, many 
variables have been explored namely; the molar ratio 
of cholesterol to that of the phospholipid, various pH 
value of hydration medium selected based on the pka of 
the drug, varying the aqueous hydration phase volume, 
incorporation of charge inducing agent and finally finding 
out the concentration of the charge imparting agent. These 
experiments were assessed by comparing the entrapment 
efficiency percentage. Table I illustrates the composition 
of different liposomes dispersions.
Physicochemical characterization of ketorolac-
loaded liposomes
Determination of entrapment efficiency (EE%)
Entrapment efficiency was calculated from 
the difference between the initial drug added during 
preparation and the free drug determined in the supernatant 
and expressed as percent entrapment efficiency, which 
is defined as the percent fraction of the total input 
drug encapsulated in the lipid bilayers and/or aqueous 
compartments in the liposome structure (Mehanna, 
Elmaradny, Samaha, 2009). Entrapment efficiency 
percentage was computed from the following equation:
 
Morphological examination of KT-loaded liposomes
Ketorolac tromethamine-loaded liposomes were 
morphologically inspected using optical microscope 
(Euromed, Holland) in order to justify their formation and 
identify their shapes. Liposome dispersions were observed 
under a binocular microscope fitted with a camera. A drop 
of liposomes dispersion was placed on a microscope slide 
(magnification power 2000), then viewed and photographed.
Transmission electron microscope examination (TEM)
Ketorolac-loaded liposomal dispersion was 
examined by TEM (JEM-100S; Joel, Tokyo, Japan); 
negatively stained sample was prepared by applying a 
drop of liposomal dispersion to copper-coated grids, after 2 
min, the excess was drawn off with filter paper. A saturated 
uranyl acetate aqueous solution was used as a staining 
agent. The excess was eliminated with distilled water 
and the samples were analyzed by transmission electron 
microscope at magnification power 10,000 at 80 KV. 
Vesicular size analysis
Liposomes  s ize  was  assessed  us ing  laser 
diffractometer (CilasL100, model 1064 l iquid; 
Quantachrom, France), Determining the mean vesicle 
size and size distribution (polydispersity) by calculating 
the span index, assures the uniformity of the liposomal 
preparation, calculated using the following equation:
Span index = Dv,90 – Dv,10 / Dv,50
where D(v,10), D(v,50) and D(v,90) are the equivalent volume 
diameters at 10, 50 and 90% cumulative volumes, 
respectively (Mehanna, Elmaradny, Samaha, 2014).
In-vitro release studies
The release of ketorolac tromethamine from the 
different liposomal dispersions was determined using 
dialysis apparatus method (Ma et al., 2008). Fixed 
volume of each formula in a 5 cm semipermeable dialysis 
membrane (Molecular weight cutoff 12,000- 14,000 
Da) tied from both sides and clamped to the paddle of 
the dissolution instrument (DT820, Erweka, Germany) 
rotating at 50 rpm, temperature kept at 34.5±1oC 
(simulating eye temperature), immersed in 250 ml 
phosphate buffer saline (PBS) as a releasing medium, 
samples were withdrawn at different time intervals and 
directly compensated with fresh PBS kept at the same 
temperature. The drug concentrations in the withdrawn 
samples were measured spectrophotometrically using PBS 
as blank at λmax 324 nm.
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Release kinetics of Ketorolac from the prepared 
liposomal dispersions, were examined based on the 
magnitude of correlation coefficients obtained after 
application of zero order, first order, and Higuchi diffusion, 
Peppeas-Korsmeyer and Hixon Crowell models (Dash et 
al., 2010).
Preparation of thermosensitive liposomal gel
Pluronic F127 polymer undergoes sol-to-gel phase 
transition upon exposure to physiological eye temperature 
– was practically found to have a gelling concentration of 
22%, was employed as a vehicle for liposomes. The gel 
preparation was performed according the cold method 
(Mehanna, Elmaradny, Samaha, 2013); where PF-127 is 
accurately weighed and slowly added to cold water (5 °C) 
with constant stirring, then refrigerated for 5 hours for 
complete polymer hydration and get rid of air bubbles which 
resulted from stirring. Liposomal PF-127 gel formula was 
prepared through dispersing KT-loaded liposomes in the 
PF-127 solutions under magnetic stirring in ice. 
Physical stability of liposomes
The physical stability of KT-loaded liposomes was 
assessed via monitoring the liposomes size and secondly, 
by chemical quantitation of entrapment efficiency 
percentage through different time intervals for six months 
at room temperature 25 °C and in refrigerator at 4 °C. In 
addition, stability of liposomes incorporated in thermo-
sensitive gel was assessed through the same time intervals 
by chemical quantitation of entrapment efficiency percent. 
RESULTS AND DISCUSSION
Optimization of ketorolac loaded-liposomal 
entrapment efficiency
Ketorolac tromethamine encapsulated within 
liposomes with a simple film hydration method was 
performed aiming to prolong the retention time of the 
drug within the eye hence enhancing its therapeutic anti-
inflammatory effect. In order to optimize the liposomes 
capacity to entrapment KT, several variables were 
studied as shown in table I. The factors investigated were; 
inclusion of cholesterol and its molar concentration, 
hydration at three different pH values, namely; pH 3, 4.2, 
and 7.4, hydration volume, and the incorporation of charge 
inducing agents, dicetyl phosphate as a negative charge 
inducing agent and stearylamine as a positive charge 
inducing agent. The effect of varying the concentration 
of the charge-inducing agent was also addressed. The 
entrapment efficiency percentage was selected as the 
determining governing response.
TABLE I - Composition of ketorolac tromethamine –loaded liposomes dispersions*
Formula Phospholipids (mg)
Cholesterol 
(mg) pH
Hydration 
volume (mL)
Dicetyl 
phosphate 
(mmol)
Stearyl amine 
(mmol)
F.1 100 0 7.4 5 -- --
F.2 100 20 7.4 5 -- --
F.3 100 33 7.4 5 -- --
F.4 100 50 7.4 5 -- --
F.5 100 50 3 5 -- --
F.6 100 50 4.2 5 -- --
F.7 100 50 7.4 5 -- --
F.8 100 50 4.2 2.5 -- --
F.9 100 50 4.2 10 -- --
F.10 100 50 4.2 5 0.5 --
F.11 100 50 4.2 5 -- 0.5
F.12 100 50 4.2 2.5 -- 0.1
F.13 100 50 4.2 2.5 -- 0.5
F.14 100 50 4.2 2.5 -- 1
* All formulation contain 1% ketorolac tromethamine
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Effect of molar cholesterol concentration 
Ketorolac tomethamine loading level in liposomes 
prepared by film hydration method was expressed as 
entrapment efficiency percentage (EE%), which was varied 
between 15 to 19%, based on the molar concentration of 
cholesterol included within the liposomes (F1-F4). This 
low entrapment efficiency can be explained as a result of 
drug high water solubility (Hou et al., 1990). 
The positive correlation between the molar 
concentration of cholesterol and EE% could be infer from 
Figure 2. This could be attributed to the hardening of the 
liposomal walls due to increase cholesterol concentration. 
Cholesterol molecules augment the structure integrity 
of liposomes bilayers membrane as it fills the spaces 
between the phospholipid molecules, in turns it reduces 
the membrane permeability and drug leakage, thus 
enhancing drug loading which was in accordance to many 
previously reported data ( Mehanna, Elmaradny, Samaha, 
2010; Hosny, 2010; Alsarra et al., 2005). Correspondingly, 
liposomes contain 50% molar cholesterol percentage was 
selected for further optimization.
Effect of hydration phase pH and volume
In order to study the influence of different pH values 
of the aqueous phase containing KT, Formulas 5, 6 and 7 
corresponding to pH 3, 4.2 and 7.4 were tested. Ketorolac 
tromethamine precipitated in pH 3 buffer during the 
preparation F5 and thus it was not possible to use it as a 
hydrating solution during the early preparation stages. This 
precipitation can be seen as a result of poor drug solubility 
in pH 3, which is below its pKa (3.5) that stopped the 
experiment early. Although the pH 7.4 is similar to 
the ocular physiological pH minimizing irritation and 
discomfort effect, still liposomes hydrated with ketorolac 
tromethamine in buffer pH 4.2 gave a higher EE% i.e. 
57%. This pH is the same for the marked FDA approved 
product. Similar results were observed by Mehanna, 
Elmaradny and Samaha (2009). Moreover, Malhotra and 
Majumdar (2002) found that ketorolac tromethamine is 
more permeable in goats’ corneas at acidic pH than pH 7.5. 
Moreover, the volume of aqueous phase was varied 
2.5-10 mL and its effect on ketorolac tromethamine 
entrapment was assessed, the highest EE% was that 
obtained with the smallest hydration volume, 2.5 mL, as 
shown in Figure 3. During the practical work, the least 
volume was observed to give a white dense colloidal 
liquid of high consistency, probably the reason for more 
efficient entrapment. These results are supported by the 
high water solubility of KT, which favor the aqueous 
medium leading to a reduction in EE% upon increasing 
the hydration volume.
Effect of incorporation and concentration of charge 
imparting agents 
Upon comparing neutrally charged liposomal 
formula (F6) to negatively charge liposomal formula 
(F10), and to positively charge liposomal formula (F11) 
by incorporation of dicetyl phosphate and stearylamine, 
respectively, it was noted that the positively charged 
liposomes had the highest EE% compared to other 
liposomes. Meanwhile, the negatively charged and the 
neutral liposomes showed lower entrapment efficiencies 
(Table II). An explanation to this observation is KT is 
negatively charged at pH 4.2 thus electrostatic attraction 
to the positive charged stearyl amine preventing ketorolac 
tromethamine from leaking outside the liposome and 
enhance its EE% in addition to the electrostatic repulsion 
between the multiple bilayers of the liposomes inducing 
an elevation of the aqueous phase inclusion within the 
liposomal bilayers and indirectly positevly influence KT 
entrapment. The higher EE% of the negatively charged 
FIGURE 2 - Entrapment efficiency of ketorolac–loaded 
liposomes with various cholesterol molar concentration.
FIGURE 3 - Effect of hydration phase pH and volume on the 
entrapment efficiency of ketorolac-loaded liposomes.
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liposomes compared to neutral vesicles is based on solely 
on the repulsion between bilayers. Similar results were 
obtained by Schaeffer and Krohn (Schaeffer, Krohn 1982). 
Whereas, Hosny (2010) has found that the entrapment 
efficiency was best in positively charged liposomes, while 
the neutral liposomes were better than the negatively 
charged liposomes this might be due to the zwitter ion 
nature of ciprofloxacin drug.
To compare the effect of varying the concentration 
of positive charge imparting agent (stearylamine) on 
KT liposomes entrapment efficiency, three formulations 
were prepared and tested using 0.1, 0.5 and 1.0 mmole 
(F12, F13 and F14, respectively. Through table 2, it could 
be observed that increasing the molar concentration of 
stearylamine was linked to increase in EE% up to 0.5 
mmole but further increase led to a reduction of KT 
entrapment. As higher stearylamine concentration may 
lead to disruption of liposomes structure and formation 
as it lacks the amphiphilic nature of phospholipids. These 
results are quite similar to Mehanna, Elmaradny and 
Samaha (2009) who reported that 0.38 molar ratio of 
stearylamine was the optimal for ciprofloxacin-loaded 
liposomes preparation. 
Morphological examination of ketorolac 
tromethamine-loaded liposomes
The microscopical examination using the optical 
microscope -magnifying at 2000x- showed well-identified 
spherical vesicular structure with large internal space 
of the liposomes as illustrated in Figure 4, liposomes 
without cholesterol appeared as transparent bi-layer, 
whereas liposomes containing cholesterol showed a 
fortified bilayers, It is agreed by many researchers that 
the incorporation of cholesterol increases the rigidity of 
the bilayer membranes (Tahaa et al., 2014; Wessman, 
Edwards, Mahlin, 2010). The transmission electron 
microscope magnifying at 10,000x showed mainly 
multilamellar liposomes with some unilamellar vesicles as 
evident in Figure 4. Several authors reported comparable 
findings (Sinico et al., 2005).
Particle size evaluation of ketorolac 
tromethamine-loaded liposomes 
The average size and size distribution are important 
parameters as to determine the mechanism of uptake by 
the cornea, as well their stability condition of liposomes 
(Gaudana et al., 2010). The particle size of nanoliposomes 
was investigated using a particle size analyzer (Zeta Sizer 
2000, Malvern Instruments, Worcestershire, UK), as 
well as transmission electron microscope that elaborated 
liposomes size range between 196-8350 nm, varying 
according to the formula of liposomes. The span index 
TABLE II - Effect of incorporation and concentration of charge imparting agents on ketorolac tromethamine -loaded liposomes 
entrapment efficiency
Formula
Charge imparting agents concentration (mMole) Entrapment 
efficiency %Dicetyl phosphate Stearylamine 
F10* 0.5 - 38
F11* - 0.5 41
F12 - 0.1 37
F13 - 0.5 63
F14 - 1 58
*Formula prepared with 5ml aqueous hydration volume
FIGURE 4 - Optical photographs (A and B) and transmission 
electron microscopical photomicrographs (C and D) of 
Ketorolac tromethamine-loaded liposomes prepared via film 
hydration method.
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indicates the uniformity of the liposomal preparation, 
the smaller the span index, and the narrower the size 
distribution. 
As evident by the results illustrated in Table III, a 
dramatic increase in the particle size of the liposomes 
upon increasing the cholesterol concentration (F1-
F4). Increasing the molar cholesterol concentration 
reflected on a significant increase in the overall size of 
the liposomes. The amphiphilic nature of cholesterol 
controls its organization within the liposomal bilayer 
membrane structure as inserts itself into the bilayer with its 
hydrophilic head oriented towards the aqueous surface and 
aliphatic chain line up parallel to the hydrocarbon chains 
in the center of the bilayers which induced the observed 
enlargement of liposomes (Xu, London, 2000). These 
results were previously reported by Tahaa et al. (2014)
who found that liposomes size increased linearly with 
increasing the cholesterol concentration. Similar effect of 
cholesterol inclusion was reported for nevirapine (Ramana 
et al., 2010). 
It is also obvious that charged liposomes (F10 & 
F11) had a larger particle size when compared to the 
neutral liposomes with the same initial components 
(F1-F4). This behaviour can be linked to the electrostatic 
repulsion between the charged molecules, which led to 
expand the spaces between the bilayers due to pushing 
the polar heads of the phospholipids outwards within 
the multilamellar structure (Hosny, 2010; Ramana et al., 
2010). A more closed examination of the results 
elaborated the influence of the nature of the charging 
inducing agent as the positively charged liposomes 
were of higher particle size than the negatively charged 
ones. This could be attributed to the bulkiness of dicetyl 
phosphate (C32 H67 O4 P) molecule with its two cetyl 
chains might have resulted in less tightly packed bilayer 
membranes compared to the less bulky stearylamine 
(C8 H15 N O8), molecule. Another possible explanation 
is the charge density that would amplify the electrostatic 
repulsion force between the dicetyl phosphate and 
cholesterol head groups having a similar charge (Samad, 
Sultana, Aqil, 2007). Therefore, the overall result showed 
that the positively charged liposomes (F11) were smaller 
than the negatively charged ones (F10) i.e. uncharged 
liposomes < positively charged < negatively charged 
liposomes. 
Therefore, it could be deduced that increasing the 
concentration of cholesterol resulted in an increase in the 
liposomes size consequently increased the entrapment 
efficiency. Thus, the particle size is directly proportional 
to the entrapment efficiency of liposomes. 
In-vitro release studies
In order to develop a liposomal drug delivery 
system for localized and sustained ocular delivery, it 
was necessary to check the release profile of different 
dispersions in conditions simulating the ocular 
environment. Since human tears are known to be 
complex, approximately isotonic solution containing 
proteins, lipids, electrolytes and other components 
with pH values in the range of 6.8-7.5 (Abelson, Udell, 
Weston, 1980). The principle-buffering agent in the eye 
is bicarbonate system, which is unstable overtime when 
used for laboratory studies. The simulated tear solution 
used was isotonic phosphate buffer (pH7.4), which was 
chosen for its pH stability, analytical non-interference 
and relationship to human tear (pH, buffering range, 
and buffering capacity). Furthermore it was desired to 
keep the simulated tear solution simple so as to prevent 
complications from possible interactions and analytical 
interference (Carney, Mauger, Hill, 1989).
The release profile of ketorolac from the optimized 
liposomal preparation (F13) was illustrated in Figure 
5. Upon comparing the release profile of the optimized 
formula of ketorolac-loaded liposomes to the marketed 
product, it was found that the release profile of ketorolac-
loaded liposomes showed the slowest release profile 
with initial burst release. This performance may be 
contributed to the desorption of the electrically attached 
drug molecules on liposomes outer surface followed by 
slower release rate of the encapsulated drug within the 
multilamellar liposomal structure (Widjaja et al., 2014).
With the intention of eliminating the burst release 
and controlling ketorolac release from liposomes. PF-
127-based liposomal gel was prepared and evaluated. 
This strategy was proved to be able to control the drug 
release over 24 h as shown in Figure 5, which illustrates 
the cumulative percent of ketorolac released as a function 
TABLE III - Particle size and size distribution indicated by Span 
Index of ketorolac tromethamine-loaded liposomes 
Formula Particle size (nm) Span Index
F1 196 0.064
F2 3270 0.960
F3 7000 0.540
F4 7050 0.390
F10 8350 0.450
F11 7060 0.430
F13 2900 0.950
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of time. The controlled release manner was mainly due 
to gel nature of PF-127 at 34.5±1 oC, which increase the 
viscosity of the diffusion layer surrounding the liposomes 
representing another barrier for drug release. The 
explanation is further supported by the kinetic analysis, 
which indicated that ketorolac release mechanism was 
a diffusion-dependent process as the best fit for kinetic 
models was Higuchi model based on the correlation 
coefficient. Comparable results were reported by several 
authors (Nagarsenker, Londhe, Nadkarni, 1999; Jain, 
Shastri, 2011).
Stability of liposomal formulation 
A stability study for six months was performed to 
assess the ability of the prepared liposomes to maintain its 
physicochemical characteristics. The optimized liposomal 
formula (F13), and the in-situ liposomal thermoresponsive 
gel were stored at 4 and 25 oC. The physical appearance 
of the liposomes formulations seemed unchanged, neither 
sedimentation nor flocculation was observed indicating the 
high physical stability of the liposomal system in general. 
The results obtained are tabulated (Table IV) showing 
that liposomal formula (F13), stored at room temperature 
(25 oC) showed a faster decrease in EE% than that of 
refrigerated liposomes (4 oC) that indicate the leakage 
of the entrapped drug from the vesicular structure. The 
elevated temperature induced energy-dependent fusion of 
liposomes via enhancing its Brownian motion in addition; 
the phospholipid became more flexible and fluid through 
increased temperature, thus the entrapped drug leaked 
easily. Comparable outcomes were obtained by Manosroi 
and Podjanasoothon (2002) who studied the effect of 
temperature on different tranexamic acid liposomal 
formulations proving that the high temperature led to 
the highest leakage of drug. Moreover, liposomal in-situ 
gelling system was able to maintain drug encapsulation at 
both temperatures compared to the liposomes dispersion. 
A more stable formulation was that stored at 25 oC, which 
might be due to the thermosensitive gel formation at 
elevated temperature. One can conclude that, liposomes 
in gel showed better retaining of the drug i.e. better EE% 
as a two barrier systems not allowing the drug to leak out 
of the liposomes. 
CONCLUSION
In the current study, the potential of liposomes 
as ketorolac vesicular carrier for ocular delivery was 
explored. A controlled release ocular dosage form based 
on ketorolac tromethamine liposomes was successfully 
formulated, optimized and characterized. It has been shown 
that liposomes prepared using fifty percent cholesterol, 
with low hydrating volume, at pH 4.2, and using a 
positive charge-imparting agent at 0.5 mM concentration, 
resulted in the highest entrapment efficiency which is the 
main key for hydrophilic drug liposomal encapsulation. 
In addition, It was found that the mechanism of release 
from the liposomes to the eye was diffusion. Liposomes 
dispersed in Pluronic F-127 in situ thermosensitive gel 
demonstrated a prolonged release over 24 h with more 
sustainability of the dose due to the dual barrier which 
the drug has to penetrate. The stability study of liposomes 
and liposomal gel at 4 and 25 °C for six months, showed 
that the liposomal gel at room temperature (25 °C) had the 
best stability. Ketorolac tromethamine-loaded liposomal 
thermoresponsive-based gel representing a practical stable 
substituent to the ordinary eye drops via its capability to 
control and prolong the drug release with reduce frequency 
of dosing and in reflect augment patient compliance which 
is a major problem in ocular therapy.
FIGURE 5 - Release profile of ketorolac tromethamine into 
phosphate buffer saline at 34.5±1oC from marketed eye drops, 
liposomes dispersion and thermosensitive liposomal gel.
TABLE IV - Influence of storage temperature on the entrapment 
efficacy of ketorolac tromethamine-loaded liposomes 
Formula Time interval (Month)
Entrapment 
efficiency %
4oC 25 oC
Liposomal aqueous 
dispersion
1 96 93
3 92 87
6 85 75
Liposomal 
thermoresponsive 
gel
1 98 99
3 92 95
6 88 92
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